Abstract: Alzheimer’s disease (AD) is the most prevalent cause of dementia. According to the Alzheimer’s Disease Association, there are over 37 million patients currently suffering from AD. To date, there is still no standard method for accurate AD diagnosis. Detection of biomarkers has become a new trend for disease diagnosis as research has shown that alternation of the expression profile of biomarkers occurs over 10 years before the development of any symptoms. Recently, there is a considerable development in the field of ultrasensitive detection assay for AD diagnosis. This perspective gives an updated review of the current state of development on body fluid-based detection assay for non-invasive AD diagnosis.

Key words: Alzheimer’s disease, biomarkers, non-invasive, diagnosis, immunoassay